Cancer Research/Cell Biology
Immunotherapy / Hematology
Lonza Optimized Protocol
The table below shows data for the cell type and Nucleofector™ Platform selected. Those data are either based on Lonza Optimized Protocols
or on results shared from customers who performed an optimization based on our guidelines. In case no data are shown for the selected Nucleofector™ Platform, please take a look at our
to get further guidance on how to easily determine optimal Nucleofection conditions yourself.
Continuous expression of Bcl-xL protein during megakaryopoiesis is post-translationally regulated by thrombopoietin-mediated Akt activation, which prevents the cleavage of Bcl-xL
Kozuma Y, Kojima H, Yuki S, Suzuki H, Nagasawa T
J Thromb Haemost (2007) 5(6): 1274-82
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I, DeAngelo DJ, Clark JJ, Lee SJ, Golub TR, Wadleigh M, Gilliland DG, Levine RL
PLoS Med (2006) 3(7): e270
Molecular and Functional Analyses of a Human Parvovirus B19 Infectious Clone Demonstrates Essential Roles for NS1, VP1, and the 11-Kilodalton Protein in Virus Replication and Infectivity
Zhi N, Mills IP, Lu J, Wong S, Filippone C, Brown KE
J Virol (2006) 80(12): 5941-5950
©2016 Lonza. All rights reserved.